Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Purchases 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction on Wednesday, March 18th. The shares were bought at an average price of $14.89 per share, with a total value of $223,350.00. Following the purchase, the chief executive officer directly owned 15,001 shares in the company, valued at approximately $223,364.89. The trade was a 1,500,000.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Tonix Pharmaceuticals Stock Down 5.1%

Shares of TNXP opened at $14.19 on Thursday. The company has a market capitalization of $190.15 million, a price-to-earnings ratio of -0.99 and a beta of 1.88. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $13.07 and a 52 week high of $69.97. The stock’s 50-day moving average price is $15.58 and its 200-day moving average price is $18.57.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The company had revenue of $5.39 million during the quarter, compared to analyst estimates of $2.97 million. As a group, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Man Group plc acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $288,000. Engineers Gate Manager LP raised its position in Tonix Pharmaceuticals by 63.7% during the fourth quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock worth $223,000 after acquiring an additional 5,550 shares during the period. Balyasny Asset Management L.P. acquired a new position in Tonix Pharmaceuticals during the fourth quarter worth $2,895,000. AQR Capital Management LLC purchased a new position in Tonix Pharmaceuticals during the fourth quarter valued at $313,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at about $171,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $70.00.

Tonix Pharmaceuticals News Summary

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: CEO Seth Lederman purchased 15,000 shares at about $14.89, a sizable insider buy that can be read as management confidence in the company’s outlook. SEC Form 4 – Lederman Insider Purchase
• Positive Sentiment: Tonix will present at BIO-Europe Spring (Mar 24); investor presentations at major partnering conferences can boost visibility for business development and licensing opportunities. Tonix to Present at BIO-Europe Spring 2026
• Positive Sentiment: Tonix announced an oral presentation and two posters on its preclinical immuno‑oncology portfolio at AACR 2026 (April). Early scientific data and conference exposure could advance partnerships or pipeline value if findings are viewed favorably. Tonix AACR Presentations
• Neutral Sentiment: Q4 results showed a revenue beat but an EPS miss, a mixed read that suggests commercial traction but ongoing profitability and margin pressure; investors may focus on upcoming guidance and cash runway details. Tonix Q4: Revenue Beat, EPS Miss
• Negative Sentiment: Noble Financial revised estimates: it cut FY2026 and some quarterly EPS forecasts (notably Q3/Q4), increasing the large year‑over‑year loss outlook—this analyst downgrade pressure likely weighs on sentiment and share price. MarketBeat – Noble Financial Estimate Changes

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.